"Association of Aspirin Use With Mortality Risk Among Older Adult Participants in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial", by Holli A. Loomans-Kropp, et al.,
JAMA Netw Open. 2019;2(12); published December 4, 2019
Quote:
Findings
This cohort study included 146152 individuals from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial and found that aspirin use 3 or more times per week was associated with reduced risk of all-cause, cancer, gastrointestinal cancer, and colorectal cancer mortality.
Results
A total of 146152 individuals (mean [SD] age at baseline, 66.3 [2.4] years; 74742 [51.1%] women; 129446 [88.6%] non-Hispanic white) were included in analysis. The median (interquartile range) follow-up time was 12.5 (8.7-16.4) years, encompassing 1822164 person-years. Compared with no use, aspirin use 1 to 3 times per month was associated with reduced risk of all-cause mortality (HR, 0.84; 95% CI, 0.80-0.88; P less than .001) and cancer mortality (HR, 0.87; 95% CI, 0.81-0.94; P less than .001). Aspirin use 3 or more times per week was associated with decreased risk of mortality of all causes (HR, 0.81; 95% CI, 0.80-0.83; P less than .001), any cancer (HR, 0.85; 95% CI, 0.81-0.88; P less than .001), GI cancer (HR, 0.75; 95% CI, 0.66-0.84; P less than .001), and CRC (HR, 0.71; 95% CI, 0.61-0.84; P less than .001).
